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Objective: Expression of microRNAs by array analysis provides unique profiles for
classifying tissues and tumors. The purpose of our study was to examine microRNA
expression in Barrett esophagus and esophageal cancer to identify potential markers
for disease progression.
Methods:MicroRNAwas isolated from 35 frozen specimens (10 adenocarcinoma, 10
squamous cell carcinoma, 9 normal epithelium, 5 Barrett esophagus, and 1 high-grade
dysplasia). MicroRNA expression was analyzed with Ambion bioarrays (Ambion,
Austin, Tex) containing 328 human microRNA probes.
Results: Unsupervised hierarchic clustering resulted in four major branches corre-
sponding with four histologic groups. One branch consisted of 7 normal epithelium
samples and 1 squamous cell carcinoma sample. The second branch consisted of 7
squamous cell carcinoma samples and 1 normal epithelium sample. The third branch
contained 4 Barrett esophagus samples and 1 squamous cell carcinoma sample. The
fourth contained all the adenocarcinoma samples and 1 sample each of Barrett esoph-
agus, normal epithelium, squamous cell carcinoma, and high-grade dysplasia. Super-
vised classification with principal component analysis determined that the normal
epithelium samples were more similar to the squamous cell carcinoma tumors,
whereas the Barrett esophagus samples were more similar to adenocarcinoma. Pair-
wise comparisons between sample types revealed microRNAs that may be markers
of tumor progression. Both mir_203 and mir_205 were expressed 2- to 10-fold lower
in squamous cell carcinoma and adenocarcinomas than in normal epithelium. The
mir_21 expression was 3- to 5-fold higher in both tumors than in normal epithelium.
Prediction analysis of microarray classified 3 Barrett esophagus samples as Barrett
esophagus, 1 as adenocarcinoma, and 1 as normal epithelium.
Conclusion: Expression profiles of miRNA distinguish esophageal tumor histology
and can discriminate normal tissue from tumor. MicroRNA expression may prove
useful for identifying patients with Barrett esophagus at high risk for progression to
adenocarcinoma.
E
sophageal adenocarcinoma (AC) has the fastest increasing incidence of any
solid tumor in the United States,1 and the 5-year survival for this disease re-
mains dismal, ranging from 14% to 22%.2-4 Whereas the incidence of esoph-
ageal squamous cell carcinoma (SCC) has been declining or has remained constant in
the United States, that of esophageal AC has increased more than 300% in the past 30
years and continues to rise.1,5-7 The most common risk factor for AC is chronic gas-
troesophageal reflux disease, which is associated with an approximately 16-fold in-
creased risk of AC and occurs in as many as 60% of patients in whom this tumor is
diagnosed.8 Gastroesophageal reflux disease causes inflammation in the distal esoph-
agus, resulting in development of the premalignant lesion known as Barrett esophagus
(BE) or intestinal metaplasia,9 and the presence of BE confers a 0.5% per patient-year
risk of development of AC.10,11 The progression of BE to AC develops through estab-
lished histologic changes: intestinal metaplasia (BE) to low-grade dysplasia to high-
grade dysplasia (HGD) to AC. HGD represents an unstable epithelium that is a marker
for concurrent occult carcinoma or for subsequent development of carcinoma, with
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BE 5 Barrett esophagus
HGD 5 high-grade dysplasia
miRNA 5 microRNA
NSE 5 normal squamous epithelium
PAM 5 prediction analysis of microarray
SCC 5 squamous cell carcinoma
such risk ranging from 25% to 80% in multiple series.12-15
The current standard of care for patients with HGD and
low operative risk factors is esophagectomy. If the patient
chooses not to undergo surgical resection or is deemed
a poor surgical candidate, alternatives such as endomucosal
resection, photodynamic therapy, or other local therapies
may be proposed.16-18 Patients are then advised to undergo
endoscopies and multiple random biopsies every three
months. Similarly, patients with low-grade dysplasia are
advised to undergo serial endoscopies, albeit less frequently,
to monitor for development of HGD.19
Dysplasia alone as a marker of malignant progression is
marred by pathologists’ differential interpretation of degrees
of dysplasia.20 Because only a subset of dysplastic lesions
progress to cancer, the challenge lies in substratification of
biopsy samples according to the probability of malignancy
development. If molecular markers of premalignancy can
be identified on small pieces of esophageal tissue obtained
endoscopically, this could lead to improved early detection
and provide objective criteria for selection of patients who
might benefit from aggressive surgical treatment.
MicroRNAs (miRNAs), a class of small, noncoding RNA
molecules first reported on in 1993,21 are posttranscriptional
regulators of gene expression that have been shown to be in-
volved in cell differentiation, proliferation, and apoptosis.
Furthermore, it has recently been demonstrated that some
miRNAs may function as either oncogenes or tumor suppres-
sor genes (oncomirs).22 Altered expression of oncomirs has
now been found in a variety of human tumors including
lung, breast, and prostate cancers,23-27 and recent reports
demonstrate a role for miRNA expression in disease progres-
sion and outcome.24,26 Although protein-coding gene expres-
sion studies have shown differences between normal
squamous epithelium (NSE) in the esophagus and BE and
between BE and AC,28,29 only one recent report on 7 patients
has determined miRNA expression in esophageal lesions.30
We hypothesized that unique miRNA expression profiles
exist to distinguish normal esophagus, BE, esophageal dys-
plasia, and esophageal cancer. Furthermore, because miRNA
expression is associated with differentiation, specific
miRNAs may become deregulated in the progression from
BE to dysplasia to AC. Identification of these differences in
miRNA expression could then discriminate patients who256 The Journal of Thoracic and Cardiovascular Surgery c Fehave a high risk for progression to cancer and who therefore




Esophageal specimens were obtained from patients undergoing
esophagectomy for malignant disease during the years 1999 through
2005 at the University of Pittsburgh Medical Center and Mount
Sinai Medical Center. This study involving human tissue was
approved by the institutional review boards at both institutions. His-
tologic confirmation of the esophageal diagnosis was performed by
the pathologist at the Mount Sinai Medical Center (M.W.).
Thirty-five frozen specimens were chosen for analysis. There
were 10 AC specimens, 10 SCC specimens, 5 BE specimens, 1
HGD lesion specimen, and 9 NSE specimens. NSE specimens
were obtained from patients undergoing esophagectomy for HGD
or cancer andwere taken from as far from themalignancy as possible.
Isolation of miRNA
Enriched miRNA was isolated from tissue specimens with the
mirVana miRNA Isolation Kit (Ambion Inc, Austin, Tex), which
allows capture of both enriched miRNA and larger RNA species
separately. Both the enriched miRNA and large RNA were quanti-
fied with a NanoDrop spectrophotometer (NanoDrop Technology,
Wilmington, Del), and integrity of the large RNA fraction was de-
termined with an Agilent Bioanalyzer (Agilent Technologies, Palo
Alto, Calif) as a surrogate for miRNA quality control. The miRNA
samples were only used in microarray experiments if the RNA integ-
rity number for the large RNA from the same specimenwas at least 6.
Labeling and Hybridization of miRNA, Scanning,
and Data Processing
Samples of miRNA from 35 esophageal specimens were labeled
with the mirVana miRNA Labeling Kit (Ambion) according to the
manufacturer protocol. The Cy5-labeled miRNA was then hybrid-
ized at 42C for 16 hours on mirVana miRNA Bioarrays (Ambion),
which contain 796 probes representing duplicate spots for each of
287 human miRNAs, 65 mouse and rat miRNAs, 33 Ambion-
predicted miRNAs, and 4 positive controls (20 replicate spots for
each positive control). The slides were then washed and scanned
with an Axon 4000B (Molecular Devices Corporation, Sunnyvale,
Calif) scanner at 100% power and a photomultiplier tube gain of
750. The microarray images were analyzed with Genepix PRO (ver-
sion 5.1; Molecular Devices), and normalization was performed
with CyclicLoess31 in R program downloaded from the Bioconduc-
tor open source project (http://www.bioconductor.org). Unsuper-
vised hierarchic clustering, differentially expressed gene analysis
among the groups, and prediction analysis of microarray (PAM)
were performed with the National Cancer Insitute BRB-ArrayTools
Version 3.4 (BRB-ArrayTools Version 3.4; Biometrics Research
Branch, National Cancer Institute, Bethesda, Md). For differentially
expressed gene analysis among four histologic types (AC, SCC,
NSE, BE), class comparison between groups of arrays was per-
formed with a random-variance F test. Genes were considered statis-
tically significant if their P value was less than .001. A stringent
significance threshold was used to limit the number of false-positive
findings. This tool also used the multivariate permutation test tobruary 2008
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10%. The false discovery rate is the proportion of the list of
genes claimed to be differentially expressed that are expected
to be false positives. For PAM, 10-fold cross validation was per-
formed with samples of four histologic types (AC, SCC, NSE,
and BE). The comparison of PAM with histologic examination
was facilitated by transforming the continuous PAM output
into binary data with a probability of 0.5 as the cut off. Principal
component analysis was performed with Partek Genomics Suite
software (Partek, Inc, St Louis, Mo).
Results
Sample Classification With Unsupervised Hierarchic
Clustering
We analyzed miRNA expression in 10 AC, 10 SCC, 5 BE, 1
HGD, and 9 NSE samples. Unsupervised hierarchic cluster-
ing of samples with all miRNAs was able to separate NSE,
SCC, BE, and AC into four major groups with a few excep-
tions (Figure 1, A). SCC sample MS305 was exceptional,
with an miRNA pattern clustered in the AC group. The his-
tologic type of MS305 was AC according to frozen-section
analysis but was later interpreted as SCC on the fixed-tissue
slides for final pathologic study. After the miRNA profile was
obtained, the fixed-tissue slides were reviewed again by a
pathologist at University of Pittsburgh Medical Center,
who determined that it was a basaloid SCC with focally un-
differentiated areas that could look like a poorly differenti-
ated AC.Significantly Differentially Expressed miRNAs
In addition to unsupervised sample classification, we also
performed analysis to identify miRNAs that were differen-
tially expressed among different histologic groups. Our
results indicated that 13 human miRNAs are significantly dif-
ferentially expressed among AC, SCC, and NSE (Table 1).
The miRNAs miR_194, miR_192, and miR_200c are signif-
icantly upregulated in AC but not in SCC. Relative to NSE,
miR_342 is differentially expressed in SCC but not AC.
Others, including miR_21, miR_205, miR_203, and
miR_93, are differentially expressed between tumor and
normal tissue but not necessarily between the two tumor
histologic types.
Supervised Sample Classification With Principal
Component Analysis
Principal component analysis was performed with signifi-
cantly differentially expressed genes (described previously)
on the 35 esophageal specimens. As with the cluster analysis,
principal component analysis was able to separate the four
main types of samples (NSE, AC, SCC, and BE) into distinct
groups. This analysis also provided a clear visual representa-
tion of similarity between the histologic types (Figure 1, B).
The NSE and SCC samples were more similar to each other
than to the AC samples. The BE samples sat between the AC
and NSE samples, and the single HGD specimen had
a miRNA expression profile similar to the AC sample.Figure 1. MicroRNA expression patterns distinguish esophageal adenocarcinoma (AC), squamous cell carcinoma
(SCC), normal squamous epithelium (NSE), Barrett esophagus (BE), and high-grade dysplasia (HGD). A, Unsupervised
hierarchic clustering of esophageal specimens with all expressed miRNAs. Linked samples (1882/1881 and MS629/
MS628) were obtained from the same patient. B, Principal component analysis mapping based on 14 miRNAs that
exhibit differential expression between adenocarcinoma (red triangle), squamous cell carcinoma (yellow circle),
normal squamous epithelium (purple hexagon), Barrett esophagus (blue square), and high-grade dysplasia (green
diamond).
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PAM identified a set of miRNAs, the expression of which
was able to classify samples accurately according to histo-
logic type. All 10 AC and 10 SCC samples were accurately
classified into the correct histologic groups, whereas 2 NSE
samples were classified incorrectly, 1 as BE and 1 as SCC.
Of the 5 BE samples, 3 were classified as BE, 1 was called
AC, and the other was classified as NSE. With the same
miRNA classifier, the single HGD sample was determined
to be more similar to AC than to the other three histologic
types. These data are shown in Table 2.
Discussion
The incidence of esophageal cancer has increased more than
300% in the United States since the 1970s, and the overall
cure rate is dismal and failing to improve. BE, the earliest
known premalignant lesion for this cancer, is associated
with a risk of cancer of 0.5% per patient-year.11,32 Current na-
tional guidelines from the American College of Gastroenter-
ology include serial endoscopies and random biopsies to
identify dysplasia and cancer in this small but high-risk pop-
ulation of patients with reflux.10,11 In addition to the potential
sampling error with random endoscopic biopsies, the inter-
pretation of dysplasia is subject to interobserver variability.
The best clinical management of these patients is therefore
still limited by our current diagnostic approach and our
understanding of the disease process.
Global gene expression (messenger RNA) profiling of BE
and esophageal cancer has previously been used to identify
differentially expressed genes in BE relative to esophageal
TABLE 1. Differentially expressed microRNAs among four
histologic types (adenocarcinoma, squamous cell
carcinoma, Barrett esophagus, and normal squamous
epithelium)
Fold change
MicroRNA AC vs BE AC vs NSE SCC vs NSE AC vs SCC FDR
hsa_miR_192 1.7 3.9 0.9 4.4 ,1e-07
hsa_miR_194 2 4.7 0.8 5.6 ,1e-07
mmu_miR_192 1.4 3.0 0.9 3.4 ,1e-07
hsa_miR_21 3.7 5.2 2.9 1.8 0.0003384
hsa_miR_27b 0.7 0.4 0.6 0.7 0.0003384
hsa_miR_205 0.9 0.1 0.5 0.3 0.0005452
hsa_miR_203 0.9 0.2 0.4 0.6 0.0009346
hsa_miR_200c 1.9 1.9 0.8 2.4 0.0014706
hsa_miR_342 0.8 0.8 1.8 0.4 0.0014706
hsa_let_7c 1.1 0.6 0.5 1.2 0.006298
hsa_miR_93 1.3 1.4 1.3 1.1 0.0107505
hsa_miR_125b 0.5 0.5 0.8 0.6 0.0107505
hsa_miR_100 0.8 0.5 0.7 0.7 0.0112511
hsa_miR_152 1 0.8 1.1 0.8 0.0147661
AC, Adenocarcinoma; BE, Barrett esophagus; NSE, normal squamous
epithelium; SCC, squamous cell carcinoma; FDR, false discovery rate.258 The Journal of Thoracic and Cardiovascular Surgery c FebAC.33 In nonesophageal tissues, miRNA expression profiling
has been shown to provide more accurate classification of tis-
sue and tumor types than global messenger RNA expression
profiles.23,34 For example, differential miRNA expression
has been used to discriminate lung cancer from benign lung
tissue, lung AC from SCC,26 and malignant from benign
tissues in the prostate and thyroid.27,35 In addition, miRNA
plays a role in lineage-specific tissue differentiation and as
such is particularly good at identifying the source of poorly
differentiated tumors of unknown origin.23 We therefore hy-
pothesized that (1) tumor-specific miRNA expression pro-
files exist for malignant and normal esophageal tissues and
(2) miRNA expression profiles may be associated with
progression from BE to AC.
To test our hypotheses, we used miRNA expression arrays
from Ambion to determine the miRNA profiles for esopha-
geal NSE, BE, an HGD lesion, and the two primary types
of esophageal cancer, AC and SCC. In this series we demon-
strated that miRNA expression profiles distinguish different
esophageal tissue types and also discriminate malignant
from normal esophageal tissue. Furthermore, the NSE and
SCC samples were much more similar to each other than to
the AC samples. Similarly, BE and AC miRNA expression
profiles were more similar to each other than to tissues of
squamous origin (either benign or malignant). In light of
our current understanding of the development of esophageal
AC, this makes good biologic sense, because AC is believed
to arise from Barrett columnar epithelium and not from squa-
mous epithelium.
In addition to identifying differential expression of partic-
ular miRNAs in NSE, BE, AC, and SCC of the esophagus,
we also used the miRNA data to predict into which groups
the BE specimens would be genotyped on the basis of
miRNA expression rather than histologic examination. This
analysis identified possible subtypes of miRNA expression
within the 5 BE samples: 1 with a ‘‘normal’’ profile, 1 with
an ‘‘AC’’ profile, and 3 with BE-specific miRNA expression.
TABLE 2. Prediction analysis of microarray classification
of samples according to miRNA expression
Classification
Histologic type No. of samples AC SCC NSE BE
AC 10 10 0 0 0
SCC 10 0 10 0 0
NSE 9 0 1 7 1
BE 5 1 0 1 3
HGD 1 1 0 0 0
Training was performed on all samples except the single high-grade dyspla-
sia with 10-fold internal cross-validation. The high-grade dysplasia sample
classification was then predicted on the basis of the training analysis but
forced into one of the histologic types used in the training. AC, Adenocarci-
noma; SCC, squamous cell carcinoma; NSE, normal squamous epithelium;
BE, Barrett esophagus; HGD, high-grade dysplasia.ruary 2008
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tients with BE undergoing cancer follow-up to examine the
hypothesis that miRNA expression may distinguish a sub-
group of BE patients most likely to have esophageal cancer
develop.
Finally, there are reports in the literature associating some
of the differentially expressed miRNAs reported on here with
other cancers. For example, miR_21 is upregulated in both
esophageal AC and SCC, and this has also been reported in
tumors of the breast, lung, prostate, colon and stomach, as
well as in glioblastomas.25,26,35,36 In addition, miR_192
and miR_203 expressions were upregulated in lung cancer
tissue relative to normal lung,36 and inhibition of miR_192
has been shown to downregulate cell growth in a lung AC
cell line.38 In our data, we saw higher expression of
miR_192 in esophageal AC but lower expression of
miR_203 in both cancer types relative to NSE of the esoph-
agus.
Conclusions
The differential miRNA expressions of BE and esophageal
ACmay lead to identification of specific markers for progres-
sion, additional molecular classification of dysplastic lesions,
and a better understanding of the biology of progression of
BE and dysplasia. Improvement in survival of patients with
AC will most likely result from new therapies that are based
on an increased understanding of the tumor biology and iden-
tification of biomarkers for earlier detection.
We thank Dr Jose´ Walewski for the use of the Axon scanner and
Dr Alyssa Krasinskas for reviewing pathology on ambiguous spec-
imens.
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Discussion
Dr Nasser K. Altorki (New York, NY). Dr Litle, I congratulate you
on a nice piece of work and nice presentation; I also congratulate
your group on bringing this new field of microRNA expression pro-
files into the field of esophageal and other thoracic malignancies,
particularly as related to using them as diagnostic tools, prognostic
tools, and, most importantly I think, as tools for target discovery and
mechanistically understanding better the biology. I think you have
shown very nicely here that microRNA expression profiles can re-
ally distinguish histologies, AC versus SCC, and I think that you
have also shown that the expression profiles can distinguish tumor
from NSE.
From a mechanistic point of view, I do not know if you have had
the opportunity to ascertain what the genomic sequence is that these
microRNAs would target, or maybe even look at the putative signal-
ing pathways that may be affected, for example, by mir-21, which,
as I understand, is overexpressed in a variety of malignancies, both
thoracic and extrathoracic, and has been found in at least one situa-
tion to target the p10 gene and its signaling pathway. I know you’ve
had some frozen tissue. I don’t know whether you were able to go
back and examine those samples, or whether that lies in your future
plans. That would be one question, the signaling pathways or the
target sequences on the genome.260 The Journal of Thoracic and Cardiovascular Surgery c FeThe other curiosity really relates to the 5 patients who had BE
that appeared to have clustered either with squamous or AC or
NSE, as I recall. Do you have any further follow-up with those pa-
tients to see whether those molecular signatures really translated into
clinically significant outcomes?
Dr Litle. Thank you, Dr Altorki. With regard to the first ques-
tion, our lab is primarily focused currently on biomarkers and detec-
tion of occult disease. We aren’t involved in signal transduction
research at this time, but certainly those are important questions.
This is a relatively new field, and a lot is still not known about micro-
RNAs in general. They are involved in cell differentiation, apopto-
sis, and proliferation, which emphasizes how little we know. Your
questions will need to be answered with future studies.
Regarding the 5 patients with BE, we don’t have any follow-up.
The next step will be to validate the results with expression data. We
have a bank of paraffin-embedded samples of dysplasia, BE speci-
mens, and more AC specimens to add to our small sample here.
We would use the microRNA expression profiles on a larger series
and then design appropriate primers for reverse transcriptase–poly-
merase chain reaction so we could complete quantitative reverse
transcriptase–polymerase chain reaction for patients with follow-
up. Ideally, we would do follow-up on patients with BE—some
with cancer and some not—so we could correlate the results. These
research questions will be addressed in a newly funded National
Institutes of Health grant.
Dr Thomas A. D’Amico (Durham, NC). How much tissue do
you need to do the microRNA testing, and can you envisage a tech-
nique that wouldn’t require endoscopy to get the same information?
Dr Litle.Youmean to get the same information as far as whether
someone has BE?
Dr D’Amico. Right. The goal is to take patients with BE or even
just reflux and determine which ones are going to have BE or cancer.
Can you envisage a way to do that without endoscopy?
DrLitle.Use of serummarkers for identifyingBE in patientswith
reflux and cancer in patients with BE unfortunately doesn’t appear to
be available in the near future. We’re not even at the point of being
able to do this efficiently by endoscopic biopsy; we currently need
enough tissue for both histologic and RNA analyses. Adequate endo-
scopic biopsy samples for molecular analysis of patients with BE
would be our goal in the near future should our hypotheses prove true.bruary 2008
